Diagnosis and Evaluation of Chronic Liver Disease (CLD)

Introduction

Chronic Liver Disease (CLD) represents a long-term decline in liver function, persisting for over six months and encompassing vital roles such as the synthesis of clotting factors, protein production, detoxification, and bile excretion. It’s characterized by a continuous cycle of inflammation, tissue damage, and regeneration within the liver parenchyma, ultimately leading to fibrosis and cirrhosis. The diverse causes of CLD range from toxins and prolonged alcohol abuse to infections, autoimmune conditions, and inherited metabolic disorders. Cirrhosis, the advanced stage of CLD, is marked by disrupted liver structure, widespread nodule formation, vascular changes, new blood vessel growth, and extracellular matrix deposition. At a cellular level, fibrosis and cirrhosis are driven by the recruitment of stellate cells and fibroblasts, while liver regeneration depends on hepatic stem cells. Chronic liver disease is a widespread health concern, making a strong focus on understanding its common causes, clinical presentations, and effective diagnosis and management crucial. Accurate Diagnosis Cld is the first critical step in managing this progressive condition and improving patient outcomes.

Etiology of Chronic Liver Disease

Chronic Liver Disease arises from a variety of causes, broadly categorized as follows:

Alcoholic Liver Disease (ALD)

ALD is a spectrum ranging from alcoholic fatty liver (with or without hepatitis), acute alcoholic hepatitis (potentially reversible), to irreversible cirrhosis. Chronic heavy alcohol consumption is a leading cause of CLD.

Non-alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic Steatohepatitis (NASH)

NAFLD is strongly linked to metabolic syndrome (obesity, hyperlipidemia, type 2 diabetes). NASH, a more severe form of NAFLD, can progress to liver fibrosis. Metabolic syndrome risk factors exacerbate NAFLD progression.

Chronic Viral Hepatitis

Chronic infections with hepatitis B, C, and D viruses are major contributors to CLD globally, especially in East Asia and Sub-Saharan Africa. Hepatitis C virus (HCV) has various genotypes with geographical distribution variations. Untreated chronic hepatitis C can lead to serious complications including hepatocellular carcinoma.

Genetic Factors

• Alpha-1 Antitrypsin Deficiency: The most common genetic cause of CLD in children.
• Hereditary Hemochromatosis: An autosomal recessive disorder causing excessive iron absorption due to HFE gene mutations, leading to iron overload, free radical production, and organ fibrosis.
• Wilson’s Disease: An autosomal recessive condition causing copper accumulation in the liver and other organs.

Autoimmune Liver Diseases

Autoimmune hepatitis involves liver parenchyma destruction by autoantibodies and often presents with pre-existing cirrhosis. It is more prevalent in females.

• Primary Biliary Cholangitis (PBC): A progressive autoimmune disease targeting intrahepatic bile ducts, causing inflammation, scarring, cholestatic jaundice, and liver fibrosis. More common in middle-aged women and associated with elevated alkaline phosphatase levels.
• Primary Sclerosing Cholangitis (PSC): Frequently associated with ulcerative colitis. PSC involves inflammation and fibrosis, leading to narrowing of intrahepatic and extrahepatic bile ducts.
• Autoimmune Hepatitis (AIH): A chronic inflammatory hepatitis, more common in women, characterized by elevated autoantibodies like antinuclear antibodies (ANA), anti-smooth muscle antibodies (ASMA), and hypergammaglobulinemia.

Other Etiologies

• Drug-induced Liver Injury: Certain medications like amiodarone, isoniazid, methotrexate, phenytoin, and nitrofurantoin can cause CLD.
• Vascular Causes: Conditions such as Budd-Chiari syndrome (hepatic vein obstruction).
• Idiopathic/Cryptogenic CLD: In approximately 15% of cases, the cause of CLD remains unknown.

Epidemiology of Chronic Liver Disease

Chronic liver disease is a significant cause of mortality worldwide, particularly in developing nations, and its prevalence is increasing. In developed countries, the primary causes include alcoholic liver disease, chronic viral hepatitis (B and C), non-alcoholic fatty liver disease (NAFLD), and hemochromatosis. In the United States, data from the CDC’s National Vital Statistics Report (2017) indicates that around 4.5 million adults suffered from chronic liver disease and cirrhosis, representing 1.8% of the adult population. CLD and cirrhosis were responsible for 41,473 deaths, a rate of 12.8 deaths per 100,000 population.

Pathophysiology of Chronic Liver Disease

CLD involves a continuous process of hepatic fibrosis, structural distortion, and nodule formation. Early fibrosis may be reversible, but the transition to irreversible fibrosis is complex. Untreated CLD typically progresses to irreversible fibrosis, regeneration nodules, and cirrhosis. The rate of fibrosis progression varies depending on the underlying cause, environmental factors, and individual host factors. Studies have shown that the rate of fibrosis development differs significantly across etiologies, being most rapid in HIV-HCV co-infection and slowest in primary biliary cirrhosis. Factors like age and sex also influence fibrosis progression rates.

Hepatic fibrosis is the accumulation of extracellular matrix (ECM) due to chronic liver injury. This process is initiated by hepatic stellate cells (HSCs), which normally store vitamin A. Upon liver injury, HSCs become activated into myofibroblasts, proliferate, and express inflammatory receptors, releasing chemokines and inflammatory mediators. This pro-inflammatory phase alters gene expression in liver cells, making them more responsive to cytokines, perpetuating HSC activation, and leading to ECM accumulation and progressive fibrosis.

Histopathology of Chronic Liver Disease

Stellate cells are the primary source of collagen in liver pathology. Chronic liver injury activates HSCs, transforming them into myofibroblast-like cells that deposit ECM. Chronic inflammation, cytokine production from damaged liver cells, and ECM disruption are key stimuli for stellate cell activation.

The pattern of liver fibrosis varies by etiology. Viral hepatitis typically causes portal expansion followed by periportal fibrosis, septal (bridging) fibrosis, and cirrhosis. Alcoholic liver disease and NAFLD often start with centrilobular perivenular and sinusoidal fibrosis. Pediatric NAFLD resembles viral hepatitis with periportal distribution. Biliary tract disease cirrhosis shows feathery degeneration of periseptal hepatocytes with “halos” and irregular nodules (“jigsaw” micronodular pattern). Venous outflow obstruction leads to veno-portal cirrhosis or veno-centric cirrhosis.

History and Physical Examination in CLD

Clinical Manifestations

CLD symptoms can be non-specific, such as fatigue, anorexia, and weight loss, or directly related to complications like portal hypertension, hepatocellular insufficiency, and hepatocellular carcinoma. Decompensated CLD can manifest with:

Portal Hypertension

Portal hypertension results from increased resistance to portal blood flow, often due to cirrhosis. A portal pressure above 7 mmHg is considered portal hypertension, but complications usually arise above 12 mmHg. Causes are categorized as prehepatic (portal vein thrombosis), hepatic (cirrhosis), and posthepatic (Budd-Chiari syndrome). Cirrhosis is the most common cause, especially in developed countries. Consequences of portal hypertension include:

• Esophageal Varices: Presenting with melena or upper GI bleeding. Variceal bleeding is a life-threatening complication of CLD.
• Caput medusae
• Rectal hemorrhoids
• Ascites: Fluid accumulation in the peritoneal cavity due to increased hydrostatic pressure, decreased oncotic pressure (low albumin), and splanchnic vasodilation. Clinical signs include abdominal distension, shifting dullness, and fluid wave. Tense ascites can cause shortness of breath or early satiety.

Hepatocellular Insufficiency

Hepatic Encephalopathy (HE)

HE is a neuropsychiatric syndrome caused by liver dysfunction. Impaired detoxification, especially of ammonia, leads to elevated ammonia levels, affecting consciousness. Approximately 50% of decompensated CLD patients develop HE. HE is graded by severity:

• Grade 0/Minimal: Subclinical, subtle cognitive changes.
• Grade 1: Mild confusion, altered sleep, attention deficits.
• Grade 2: Lethargy, disorientation to time, personality changes, asterixis.
• Grade 3: Somnolence to stupor, confusion, bizarre behavior.
• Grade 4: Coma.

Symptoms vary, but altered sensorium is common. Infections, GI bleeding, hyperkalemia, TIPS, sedatives, and alkalosis can worsen HE.

Jaundice

Jaundice is yellowing of skin and mucous membranes due to bilirubin overproduction or under-clearance. In CLD, impaired bilirubin conjugation leads to tissue deposition. Jaundice is visible when bilirubin exceeds 2 mg/dL. Bile salt accumulation causes pruritus.

Spontaneous Bacterial Peritonitis (SBP)

SBP is a severe complication where bacteria (e.g., E. coli, Klebsiella, Streptococcus pneumoniae) infect ascitic fluid, causing fever, abdominal pain, tenderness, and reduced bowel sounds.

Hyperestrinism

Impaired estrogen catabolism in CLD leads to excess estrogen, manifesting as palmar erythema, spider angiomas, gynecomastia, and testicular atrophy.

Hepatorenal Syndrome (HRS)

HRS is functional renal failure in the context of advanced liver disease. It’s characterized by renal vasoconstriction. Diagnostic criteria include:

• Chronic liver disease with portal hypertension.
• Rising creatinine (≥0.3 mg/dL in 48 hours or doubling in 7 days).
• Oliguria, minimal proteinuria.
• Urine sodium <10 mEq/L.
• No improvement with volume expansion, diuretic cessation.
• Absence of shock, nephrotoxic drugs, or renal disease.

Coagulopathy

Impaired clotting factor synthesis in CLD leads to coagulopathy, causing easy bruising and bleeding. PT/INR and APTT are prolonged.

Evaluation and Diagnosis of Chronic Liver Disease

The diagnosis cld relies on identifying the underlying cause and assessing the complications. A comprehensive approach is needed, integrating clinical history, physical examination, laboratory tests, and imaging.

Diagnostic Approach for Specific CLD Etiologies:

• Viral Hepatitis B and C: Serological tests, PCR (quantitative and qualitative) with genotype determination are crucial for diagnosis cld caused by viral hepatitis.
• Alcoholic Liver Disease: History of chronic alcohol use, elevated AST>ALT (AST:ALT ratio typically >2:1) are suggestive in diagnosis cld related to alcohol.
• Hemochromatosis: Elevated serum iron, ferritin, decreased TIBC, and liver biopsy. Genetic testing for HFE gene mutations (e.g., C282Y) aids in diagnosis cld.
• Wilson’s Disease: Increased urine copper, decreased serum ceruloplasmin, and liver biopsy. Genetic testing for ATP7B gene mutation is helpful in diagnosis cld.
• Non-alcoholic Fatty Liver Disease (NAFLD): Diagnosis of exclusion, often with ALT>AST. Liver ultrasonography is informative for diagnosis cld.
• Autoimmune Hepatitis: Elevated ANA, ASMA, and LKM-1 autoantibodies support diagnosis cld.
• Alpha-1 Antitrypsin Deficiency: Low serum alpha-1 antitrypsin levels are diagnostic for this cause of diagnosis cld.
• Primary Biliary Cholangitis (PBC): Markedly elevated alkaline phosphatase with antimitochondrial antibody (AMA) is key for diagnosis cld.
• Budd-Chiari and Veno-occlusive Disease: CBC, clotting profile, and imaging (ultrasound Doppler or CT with contrast) are used in diagnosis cld.

Laboratory Investigations for CLD Diagnosis

Liver function tests (LFTs) are central to diagnosis cld:

• Aminotransferases (AST and ALT): Elevated due to hepatocyte inflammation and damage. Usually 2-3 times the normal limit, but normal levels do not exclude cirrhosis.
• Alkaline Phosphatase (ALP) and Gamma-glutamyl transferase (GGT): Elevated in cholestatic conditions like PBC.
• Bilirubin: Elevated (unconjugated > conjugated) in jaundice.
• Prothrombin Time/INR and APTT: Prolonged due to reduced clotting factor production.
• Albumin: Decreased due to hepatocellular insufficiency.
• Ammonia: Elevated, contributing to hepatic encephalopathy.

Ascites Evaluation: Diagnostic paracentesis is essential to determine the cause of ascites. Serum-ascites albumin gradient (SAAG) > 1.1 suggests portal hypertension. Ascitic fluid WBC > 500/µL or PMN > 250/µL and positive cultures indicate SBP.

Hepatocellular Carcinoma (HCC) Screening: Abdominal ultrasound and serum AFP levels are used for HCC surveillance in CLD patients.

Hepatorenal Syndrome (HRS) Diagnosis: Elevated creatinine (>1.5 g/dL) is a key finding in HRS.

Thrombocytopenia: Can be an indirect indicator of splenomegaly secondary to portal hypertension in CLD.

Radiologic Investigations for CLD Diagnosis

Imaging plays a crucial role in diagnosis cld and assessing its complications:

• Abdominal Ultrasound: Affordable and widely available. Detects liver size, echogenicity, and nodularity, aiding in cirrhosis diagnosis cld. Also assesses portal vein diameter (increased in portal hypertension) and identifies clots in hepatic or portal veins.
• Computed Tomography (CT) Scan: More detailed imaging for liver lesions and biliary obstruction. Triphasic CT is the choice for HCC diagnosis cld.
• Transient Elastography (FibroScan): Detects early cirrhosis and cardiovascular damage in NAFLD. Measures liver stiffness using shear wave velocity. Effective for cirrhosis diagnosis cld according to EASL guidelines.
• Wedge Hepatic Venous Pressure (WHVP): Measures portal venous pressure.
• Doppler Ultrasound: Diagnoses Budd-Chiari syndrome and portal vein thrombosis.
• Electroencephalogram (EEG): Shows delta waves in hepatic encephalopathy.
• Upper Endoscopy: Diagnoses and treats esophageal varices, assesses variceal size.
• Liver Biopsy: Confirms the diagnosis cld and assesses etiology and fibrosis stage. Can be performed via laparoscopy, transjugular, or percutaneously.

Treatment and Management of Chronic Liver Disease

Treatment and Prophylaxis

The primary goals of CLD treatment are to halt disease progression, manage complications, and improve quality of life. This requires a multidisciplinary approach. Management principles include addressing the underlying cause, managing portal hypertension, and providing specific treatments for individual conditions.

General Management of CLD Complications:

• Esophageal Varices: Management of variceal bleeding involves fluid resuscitation, vasopressors (octreotide, terlipressin), and endoscopic interventions (band ligation, sclerotherapy). Early TIPS may improve survival in some cases. Propranolol is used for primary and secondary prophylaxis.
• Ascites: Diuretics (furosemide, spironolactone) and sodium restriction are essential. Therapeutic paracentesis is used for tense ascites, with albumin infusion considered.
• Spontaneous Bacterial Peritonitis (SBP): Initial treatment with broad-spectrum antibiotics, followed by targeted antibiotics based on cultures.
• Hepatic Encephalopathy (HE): Treat precipitating factors. Lactulose and rifaximin are used to reduce ammonia levels. Lactulose promotes ammonia excretion and relieves constipation. Rifaximin reduces ammonia production by gut bacteria.
• Hepatorenal Syndrome (HRS): Liver transplant is curative. Management includes norepinephrine or terlipressin with albumin, or midodrine and octreotide with albumin. TIPS may be helpful.
• Hepatocellular Carcinoma (HCC): Treatment based on Barcelona Clinic Liver Cancer (BCLC) staging:
  • Early stage (single lesion): Resection or ablation.
  • Intermediate stage: Transarterial chemoembolization (TACE) or radioembolization.
  • Metastatic disease: Sorafenib.

Specific Treatments for CLD Etiologies:

• Viral Hepatitis: Antiviral therapy with nucleoside/nucleotide analogs or direct-acting antivirals (DAAs) to achieve viral suppression or eradication. Interferon-alpha may be used in certain cases.
• Alcoholic Liver Disease: Alcohol abstinence is crucial.
• Non-alcoholic Fatty Liver Disease: Management of metabolic syndrome components (weight loss, diabetes control, lipid management).
• Autoimmune Hepatitis: Corticosteroids and other immunosuppressants.
• Hereditary Hemochromatosis: Phlebotomy or iron chelators.
• Wilson’s Disease: Copper chelators.
• Alpha-1-Antitrypsin Deficiency: Liver transplantation.
• Drug-induced Liver Injury: Discontinuation of the offending drug.
• Primary Biliary Cholangitis (PBC): Ursodeoxycholic acid (UDCA).
• Primary Sclerosing Cholangitis (PSC): Liver transplantation.
• Budd-Chiari Syndrome: Anticoagulation, thrombolysis, angioplasty with or without stenting, TIPS, or liver transplant.

Differential Diagnosis of Chronic Liver Disease

When considering diagnosis cld, it’s important to differentiate it from other conditions with similar presentations:

• Constrictive pericarditis
• Cor pulmonale
• Dilated cardiomyopathy
• Inferior vena cava thrombosis
• Nodular regenerative hyperplasia
• Sarcoidosis
• Schistosomiasis

Staging of Liver Disease

Liver disease progression is staged as follows:

1. Hepatitis or steatosis or hepatosteatosis
2. Fibrosis
3. Cirrhosis
4. Hepatocellular carcinoma (HCC)

Prognosis of Chronic Liver Disease

Compensated CLD generally has a better prognosis than decompensated cirrhosis. Decompensated cirrhosis (with variceal bleeding, ascites, HCC, SBP, HRS) carries a poor prognosis. Mean survival is approximately six months with a Child-Pugh score ≥12 or MELD score ≥21.

Scoring systems to assess CLD severity:

1. Child-Pugh Score: Uses ascites, bilirubin, albumin, PT, and encephalopathy.

   • Class A (5-6 points): Well-compensated.
   • Class B (7-9 points): Functional compromise.
   • Class C (10-15 points): Decompensated.

2. MELD (Model for End-stage Liver Disease) Score: Uses bilirubin, serum creatinine, and INR. Predicts mortality and prioritizes liver transplant allocation.

Complications of Chronic Liver Disease

Complications of CLD include:

• Variceal bleeding
• Ascites and spontaneous bacterial peritonitis (SBP)
• Hepatic encephalopathy
• Hepatorenal syndrome
• Hepatopulmonary syndrome
• Hepatocellular carcinoma (HCC)

Consultations for Chronic Liver Disease

• Gastroenterology/hepatology for decompensated CLD.
• Nephrology for hepatorenal syndrome.
• Dietitian for nutritional advice.
• Transplant center referral for transplant evaluation.

Deterrence and Patient Education for Chronic Liver Disease

Patient education is vital in preventing CLD progression. Lifestyle modifications and preventive measures are critical:

Preventive Recommendations:

• Abstain from alcohol.
• Regular screening for hepatitis B and C.
• Hepatitis A and B vaccination.
• Avoid iron supplements unless iron deficiency is confirmed.
• Limit over-the-counter painkillers (aspirin, acetaminophen) and hepatotoxic drugs.
• Maintain a healthy lipid profile to prevent NAFLD.

Pearls and Other Key Considerations in CLD Management

Surveillance is essential to prevent complications. Regular monitoring (CBC, CMP, prothrombin time) 3-4 times yearly is recommended.

Routine endoscopy for asymptomatic esophageal varices is recommended, with follow-up endoscopy every 2 years if no varices are initially found. Nonselective beta-blockers are used for primary prophylaxis of variceal bleeding in patients with varices. Prophylactic endoscopic variceal banding is considered for large varices.

Enhancing Healthcare Team Outcomes in Chronic Liver Disease

An interprofessional team approach is crucial for optimal CLD management. Early identification of complications improves prognosis. The team includes primary care physicians, gastroenterologists/hepatologists, dieticians, social workers, and community nurses. Routine labs, endoscopy, and ultrasound are important. Liver transplant teams should closely monitor transplant candidates.

Review Questions

(Note: Review questions are expected in the original article but not included in this rewritten version as per instructions)

References

(Same references as in the original article)

1.Heidelbaugh JJ, Bruderly M. Cirrhosis and chronic liver failure: part I. Diagnosis and evaluation. Am Fam Physician. 2006 Sep 01;74(5):756-62. [PubMed: 16970019]

2.Poynard T, Mathurin P, Lai CL, Guyader D, Poupon R, Tainturier MH, Myers RP, Muntenau M, Ratziu V, Manns M, Vogel A, Capron F, Chedid A, Bedossa P., PANFIBROSIS Group. A comparison of fibrosis progression in chronic liver diseases. J Hepatol. 2003 Mar;38(3):257-65. [PubMed: 12586290]

3.Bataller R, North KE, Brenner DA. Genetic polymorphisms and the progression of liver fibrosis: a critical appraisal. Hepatology. 2003 Mar;37(3):493-503. [PubMed: 12601343]

4.Tsuchida T, Friedman SL. Mechanisms of hepatic stellate cell activation. Nat Rev Gastroenterol Hepatol. 2017 Jul;14(7):397-411. [PubMed: 28487545]

5.Lo RC, Kim H. Histopathological evaluation of liver fibrosis and cirrhosis regression. Clin Mol Hepatol. 2017 Dec;23(4):302-307. [PMC free article: PMC5760001] [PubMed: 29281870]

6.Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD, Weissenborn K, Wong P. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014 Aug;60(2):715-35. [PubMed: 25042402]

7.Dissegna D, Sponza M, Falleti E, Fabris C, Vit A, Angeli P, Piano S, Cussigh A, Cmet S, Toniutto P. Morbidity and mortality after transjugular intrahepatic portosystemic shunt placement in patients with cirrhosis. Eur J Gastroenterol Hepatol. 2019 May;31(5):626-632. [PubMed: 30550458]

8.Ellis G, Goldberg DM, Spooner RJ, Ward AM. Serum enzyme tests in diseases of the liver and biliary tree. Am J Clin Pathol. 1978 Aug;70(2):248-58. [PubMed: 696683]

9.Cordoba J, Blei AT. Brain edema and hepatic encephalopathy. Semin Liver Dis. 1996 Aug;16(3):271-80. [PubMed: 8989813]

10.Zieve L, Doizaki WM, Zieve J. Synergism between mercaptans and ammonia or fatty acids in the production of coma: a possible role for mercaptans in the pathogenesis of hepatic coma. J Lab Clin Med. 1974 Jan;83(1):16-28. [PubMed: 4808653]

11.Donovan JP, Schafer DF, Shaw BW, Sorrell MF. Cerebral oedema and increased intracranial pressure in chronic liver disease. Lancet. 1998 Mar 07;351(9104):719-21. [PubMed: 9504517]

12.Grippon P, Le Poncin Lafitte M, Boschat M, Wang S, Faure G, Dutertre D, Opolon P. Evidence for the role of ammonia in the intracerebral transfer and metabolism of tryptophan. Hepatology. 1986 Jul-Aug;6(4):682-6. [PubMed: 2426170]

13.Reinehr R, Görg B, Becker S, Qvartskhava N, Bidmon HJ, Selbach O, Haas HL, Schliess F, Häussinger D. Hypoosmotic swelling and ammonia increase oxidative stress by NADPH oxidase in cultured astrocytes and vital brain slices. Glia. 2007 May;55(7):758-71. [PubMed: 17352382]

14.Hoefs JC. Serum protein concentration and portal pressure determine the ascitic fluid protein concentration in patients with chronic liver disease. J Lab Clin Med. 1983 Aug;102(2):260-73. [PubMed: 6864073]

15.Lombardi R, Petta S, Pisano G, Dongiovanni P, Rinaldi L, Adinolfi LE, Acierno C, Valenti L, Boemi R, Spatola F, Craxì A, Fargion S, Fracanzani AL. FibroScan Identifies Patients With Nonalcoholic Fatty Liver Disease and Cardiovascular Damage. Clin Gastroenterol Hepatol. 2020 Feb;18(2):517-519. [PubMed: 30528844]

16.Jiang Q, Jiang XH, Zheng MH, Jiang LM, Chen YP, Wang L. Rifaximin versus nonabsorbable disaccharides in the management of hepatic encephalopathy: a meta-analysis. Eur J Gastroenterol Hepatol. 2008 Nov;20(11):1064-70. [PubMed: 19047837]

17.Sharma P, Sharma BC. Disaccharides in the treatment of hepatic encephalopathy. Metab Brain Dis. 2013 Jun;28(2):313-20. [PubMed: 23456517]

18.Kalambokis G, Economou M, Fotopoulos A, Al Bokharhii J, Pappas C, Katsaraki A, Tsianos EV. The effects of chronic treatment with octreotide versus octreotide plus midodrine on systemic hemodynamics and renal hemodynamics and function in nonazotemic cirrhotic patients with ascites. Am J Gastroenterol. 2005 Apr;100(4):879-85. [PubMed: 15784036]

19.Duvoux C, Zanditenas D, Hézode C, Chauvat A, Monin JL, Roudot-Thoraval F, Mallat A, Dhumeaux D. Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study. Hepatology. 2002 Aug;36(2):374-80. [PubMed: 12143045]

20.Ochs A, Rössle M, Haag K, Hauenstein KH, Deibert P, Siegerstetter V, Huonker M, Langer M, Blum HE. The transjugular intrahepatic portosystemic stent-shunt procedure for refractory ascites. N Engl J Med. 1995 May 04;332(18):1192-7. [PubMed: 7700312]

21.Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, Zhu AX, Murad MH, Marrero JA. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018 Jan;67(1):358-380. [PubMed: 28130846]

22.Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De Greve J, Douillard JY, Lathia C, Schwartz B, Taylor I, Moscovici M, Saltz LB. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006 Sep 10;24(26):4293-300. [PubMed: 16908937]

23.Gong Y, Huang Z, Christensen E, Gluud C. Ursodeoxycholic acid for patients with primary biliary cirrhosis: an updated systematic review and meta-analysis of randomized clinical trials using Bayesian approach as sensitivity analyses. Am J Gastroenterol. 2007 Aug;102(8):1799-807. [PubMed: 17459023]

24.D’Amico G, Pagliaro L, Bosch J. The treatment of portal hypertension: a meta-analytic review. Hepatology. 1995 Jul;22(1):332-54. [PubMed: 7601427]

25.Bruix J, Sherman M., American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology. 2011 Mar;53(3):1020-2. [PMC free article: PMC3084991] [PubMed: 21374666]

Disclosure: Ashish Sharma declares no relevant financial relationships with ineligible companies.

Disclosure: Shivaraj Nagalli declares no relevant financial relationships with ineligible companies.